Skip to content
Screener

Alnylam Pharmaceuticals ALNY Operating Lease Liabilities

Operating Lease Liabilities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$262.48M+59.7%
Arrowhead Research logo
Arrowhead ResearchARWR
$100.11M-6.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$90.07M+22.4%
Assembly Biosciences logo
Assembly BiosciencesASMB
$1.9M-23.7%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$0-100%
Wave Life Sciences logo
Wave Life SciencesWVE
$40.08M+195%

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$28.92B-48.5%
Enterprise value$27.47B-50.3%
P/E39.5×—
P/S6×-16.8×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%—
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062
Line itemJune 30, 2026December 31, 2025
Deferred revenue4,0144,845
Liabilities related to the sale of future royalties and development funding258,570220,068
Total current liabilities1,512,5131,466,349
Operating lease liabilities, net of current portion210,495225,087
Convertible debt1,010,9811,007,784
Liabilities related to the sale of future royalties and development funding, net of current portion1,461,5101,470,341
Other liabilities9,1527,594
Total liabilities4,204,6514,177,155

Cover / Front Matter

FAQ

What is Alnylam Pharmaceuticals's operating lease liabilities?
Alnylam Pharmaceuticals (ALNY) reported operating lease liabilities of $210.5M in Q2 2026.
How has Alnylam Pharmaceuticals's operating lease liabilities changed year-over-year?
Alnylam Pharmaceuticals's operating lease liabilities decreased by 6.2% year-over-year, from $224.45M to $210.5M.
What is the long-term trend for Alnylam Pharmaceuticals's operating lease liabilities?
Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's operating lease liabilities has grown at a -5.1% compound annual growth rate (CAGR), from $293.04M to $225.09M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Alnylam Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude